GENT.OL

Healthcare Medical Devices

Gentian Diagnostics ASA

NOK 38.60
+0.80 +2.12% today Live

Price History

Not enough data
Price chart data
DatePrice
Oct 7, 2026, live at 12:28 PM ET38.60

Key Stats

Market Cap
596.70M
Avg Volume
3,574
EPS
-NOK 0.55
52W High
NOK 60.00
52W Low
NOK 33.50
Div. Yield
1.6%

Analyst Ratings

Buy
0
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
14.96
P/B Ratio
3.27
P/S Ratio
3.28
EV/EBITDA
20.39
EV/Revenue
2.90

Margins

Gross Margin 55.5%
Operating Margin 11.9%
Net Margin (4.6%)
EBITDA Margin 14.2%

Growth & Returns

Revenue Growth (YoY)
14.2%
Return on Equity
(4.4%)
Return on Assets
6.3%

Liquidity & Leverage

Current Ratio
7.43
Quick Ratio
5.20
Debt / Equity
0.09
Total Cash
79.34M
Total Debt
16.81M

About

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

www.gentian.com